Testing immunotherapy plus targeted drug with short chemo for esophagus cancer
Part of Cancer clinical trials.
This Phase 2 study tests whether combining camrelizumab (immunotherapy) and apatinib (a targeted drug) with short-course chemotherapy can control advanced esophageal squamous cell carcinoma. It may help by improving cancer response and slowing disease growth if you’re eligible and haven’t had prior whole-body (systemic) anti-cancer treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18–75 years old and were assigned male or female at birth.
- Your esophageal squamous cell carcinoma is advanced, recurrent, or has spread, and cannot be treated with a curative (radical) approach.
- You haven’t had any prior whole-body anti-cancer treatment, or if you had chemo with curative-intent treatment before, it must have been more than 6 months ago.
- A scan shows at least one measurable tumor area that hasn’t been treated with radiotherapy before (unless that area clearly grew after treatment).
- You can provide tumor tissue for biomarker testing (like PD-L1), and your performance status is good (ECOG 0–1).
- Your blood tests and organ function meet safety limits (for example, enough white blood cells, platelets, and kidney/liver function), and you can swallow pills.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new immunotherapy drug (camrelizumab) combined with standard chemotherapy and radiation to treat advanced esophageal cancer while avoiding surgery if possible. The goal is to shrink the tumor and help you keep your esophagus working.
This trial tests a combination of three drugs (adebrelimab, apatinib, and a chemotherapy pill) for people with advanced esophageal cancer whose previous immunotherapy treatment stopped working. The goal is to see if this new combination can help the immune system fight the cancer again.
This trial tests whether giving the immunotherapy drug camrelizumab together with chemotherapy before surgery can help people with esophageal cancer avoid needing full removal of the esophagus. It aims to preserve the esophagus while still treating the cancer effectively.
This trial tests a combination of radiation, chemotherapy (cisplatin and paclitaxel), and an immunotherapy drug called camrelizumab for patients with advanced esophageal squamous cell carcinoma that cannot be surgically removed. The goal is to see if adding immunotherapy improves outcomes compared to standard treatment alone.
This study tests whether adding camrelizumab (an immune treatment) to standard chemoradiotherapy can control advanced esophageal squamous cell cancer. It is meant for people who have not had any prior whole-course cancer medicines for this cancer stage.
This Phase 2 study tests whether adding an immunotherapy drug (camrelizumab) to standard chemo-radiation can help some people with operable esophagus cancer avoid immediate surgery, using a “watch and wait” approach. If it works, it may reduce the need for early surgery for carefully selected patients.
Hear when a new Esophageal Cancer by AJCC V8 Stage trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.